Medifast financials
$11.61−0.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.4M | $76.0M | $75.1M | $89.4M | $105.6M | $115.7M | $119.0M | $140.2M | $168.6M | $174.7M | $191.0M | $235.9M |
| Gross profit | $53.4M | $51.8M | $52.1M | $62.2M | $76.6M | $84.2M | $88.2M | $105.7M | $123.4M | $127.3M | $141.4M | $177.4M |
| Gross margin | 69.9% | 68.1% | 69.4% | 69.5% | 72.6% | 72.8% | 74.1% | 75.4% | 73.2% | 72.8% | 74.0% | 75.2% |
| Operating income | -$4.3M | -$3.3M | -$7.8M | -$4.1M | -$1.1M | -$1.3M | $709.0K | $2.1M | -$7.9M | $7.9M | $8.7M | $25.5M |
| Net income | -$3.1M | -$2.1M | -$18.1M | -$2.3M | $2.5M | -$772.0K | $801.0K | $1.1M | -$8.2M | $8.3M | $6.0M | $23.1M |
| Net margin | −4.1% | −2.8% | −24.1% | −2.5% | 2.3% | −0.7% | 0.7% | 0.8% | −4.8% | 4.8% | 3.2% | 9.8% |
| Diluted EPS | $-0.28 | $-0.19 | $-1.66 | $-0.21 | $0.22 | $-0.07 | $0.07 | $0.10 | $-0.75 | $0.76 | $0.55 | $2.12 |
| EBITDA | -$881.0K | $188.0K | -$4.3M | -$1.0M | $3.0M | $2.0M | $3.9M | $5.2M | -$4.6M | $11.0M | $8.7M | $28.9M |
| Operating cash flow | $1.7M | $260.0K | -$5.3M | $12.1M | -$3.4M | $3.4M | -$4.9M | $9.1M | $13.1M | $7.3M | $10.5M | $29.9M |
| Free cash flow | $727.0K | -$836.0K | -$6.6M | $10.8M | -$4.8M | $1.9M | -$7.2M | $7.7M | $11.1M | $5.4M | $9.6M | $28.3M |
| Diluted shares | 11.1M | 11.0M | 10.9M | 11.0M | 11.1M | 10.9M | 11.0M | 11.0M | 10.9M | 11.0M | 10.9M | 10.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $71.9M | $71.5M | $89.3M | $99.5M | $101.7M | $91.7M |
| Short-term investments | $97.9M | $97.4M | $78.0M | $74.0M | $61.0M | $72.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $260.4M | $252.0M | $248.0M | $268.2M | $269.3M | $280.0M |
| Total liabilities | $64.0M | $54.4M | $49.1M | $53.5M | $53.3M | $69.1M |
| Shareholders' equity | $196.4M | $197.7M | $198.9M | $214.7M | $216.0M | $211.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology